Invitation to Immunovia’s telephone conference on Thursday, the 9th of August, 2018 at 15:00 (CET) Due to today's announcement of the non-small cell lung cancer (NSCLC) collaborative study with a major global pharma company, Immunovia invites to a telephone conference today on August 9, at 15:00 (CET). The presentation will be held in English.

Immunovia Announces Investor Relations Changes Mon, Dec 07, 2020 17:15 CET. LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber, Senior Director of Investor Relations has stepped

De senaste tweetarna från @immunovia “Vi uppskattar alla de insatser som Julie bidragit med sedan hon anslöt sig till Immunovias team som IR-ansvarig. Vi tackar henne för den här tiden på Immunovia”, säger Patrik Dahlen. Immunovia är ett diagnostikföretag som utvecklar och kommersialiserar blodtest för tidig upptäckt av cancer och autoimmuna sjukdomar. Om Immunovia Immunovia AB är ett diagnostikföretag som utvecklar och kommersialiserar blodtest med hög säkerhet för tidig upptäckt av cancer och autoimmuna sjukdomar baserade på Immunovias egenutvecklade testplattform IMMray®. “Immunovia’s strategic communications plan and IR function needs to adapt to support the company’s continued development a nd we look forward to Julie’s contribution to helps us do that.” For more information, please contact: Julie Silber Director of Investor Relations Email: julie.silber@immunovia.com Telephone: +46 7 93 486 277 Immunovia är ett bioteknikbolag. Bolagets forskning och utveckling är fokuserad mot molekylärdiagnostik, där verksamheten inriktar sig på att driva utveckling och förändring av dagens arbetsmetoder för diagnostisering av komplexa cancerformer och immuna sjukdomar.

För ytterligare information, vänligen kontakta: Patrik Dahlen, VD Immunovia Email: [email protected] Tel: +46 73 376 76 64 . Om LUND, SVERIGE - Immunovia AB (publ) ("Immunovia"), ett diagnostikföretag nära kommersiell fas som utvecklar en banbrytande antikroppsbaserad multiplex microarray-teknologiplattform för tidig upptäckt av cancer som går under namnet IMMray®, meddelar idag att Julie Silber, Senior Director of Investor Relations, per den 30 november 2020 har avslutat sin tjänst för att anta nya utmaningar. LUND, Sweden, Feb. 12, 2019 /PRNewswire/ -- (Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of Immunovia AB: Immunovia Announces Investor Relations Changes ”We appreciate the many contributions Julie made since joining the Immunovia team as Director of IR. We would like to thank Julie for her time at Immunovia,” stated Patrik Dahlen, CEO of Immunovia. Immunovia är ett bioteknikbolag. Bolagets forskning och utveckling är fokuserad mot molekylärdiagnostik, där verksamheten inriktar sig på att driva utveckling och förändring av dagens arbetsmetoder för diagnostisering av komplexa cancerformer och immuna sjukdomar. Immunovias vd Patrik Dahlen tar över ansvaret för investerarrelationer.

Kempen inleder bevakning av Immunovia med en köprekommendation och en riktkurs på 240 kronor. 16 maj 2019 09:21. ir-chefer och aktieproffs.

Tax-exempt organizations may not have an obligation to pay taxes, but these entities still have forms to fill out like anyone else. Form 990 is one of the most important of these documents. Filing this form accurately and in a timely manner

Resultaten från verifieringsstudien för Immray Pancan-d är både kliniskt relevanta och statistiskt signifikanta, förklarar Immunovias IR-chef Julie Silber i en kort kommentar till Finwire. "För att kunna gå vidare med den blinda valideringsstudien måste de vara statistiskt signifikanta", tillägger hon.

De senaste tweetarna från @immunovia

Vi tackar henne för den här tiden på Immunovia," säger Patrik Dahlen, VD för Immunovia. Country. Sweden. Exchange. Spotlight. Segment. Visit their IR Page Immunovia AB. Total report 33.

Om LUND, SVERIGE - Immunovia AB (publ) ("Immunovia"), ett diagnostikföretag nära kommersiell fas som utvecklar en banbrytande antikroppsbaserad multiplex microarray-teknologiplattform för tidig upptäckt av cancer som går under namnet IMMray®, meddelar idag att Julie Silber, Senior Director of Investor Relations, per den 30 november 2020 har avslutat sin tjänst för att anta nya utmaningar. LUND, Sweden, Feb. 12, 2019 /PRNewswire/ -- (Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of Immunovia AB: Immunovia Announces Investor Relations Changes ”We appreciate the many contributions Julie made since joining the Immunovia team as Director of IR. We would like to thank Julie for her time at Immunovia,” stated Patrik Dahlen, CEO of Immunovia. Immunovia är ett bioteknikbolag.
Di banking questions

Online-mötet kommer att innehålla presentationer av Immunovias Styrelseordförande Carl Borrebaeck, VD Mats Immunovia AB: Immunovia Announces Investor Relations Changes ”We appreciate the many contributions Julie made since joining the Immunovia team as Director of IR. We would like to thank Julie for her time at Immunovia,” stated Patrik Dahlen, CEO of Immunovia. Immunovia AB (OTCPK:IMMVF) Q1 2020 Earnings Conference Call April 28, 2020 10:30 AM ET. Company Participants. Mats Grahn - CEO. Julie Silber - our IR Director.

"För att kunna gå vidare med den blinda valideringsstudien … LUND Sweden, Dec. 7, 2020 /PRNewswire/ --Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber, Senior Director of Investor Relations has stepped down from her position to pursue other opportunities Our Investor Relations pages present published information about INVISIO, the share, ownership structure and data on future information and presentation events. LUND, SVERIGE - (Nasdaq Stockholm: IMMNOV) Immunovia har anlitat Julie Silber som Director of Investor Relations i syfte att stärka bolagets IR- och aktieägarko Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early 2020-07-01 Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than LUND, SWEDEN - (Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of Immunovia AB announces appointment of Senior Director of Investor Relations Tue, Feb 12, 2019 13:57 CET. LUND, SWEDEN - (Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director of Investor Relations. "We appreciate the many contributions Julie made since joining the Immunovia team as Director of IR. We would like to thank Julie for her time at Immunovia," stated Patrik Dahlen , CEO of LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced the company will host a Virtual Investor Day on Tuesday, June 30, 2020, from 2:00 to 4:00 pm CET. The online event will feature presentations by Immunovia’s Chairman, Carl Borrebaeck; CEO, Mats Grahn; Chief Commercial Officer, Laura Chirica; Senior VP Sales North America, Michael Pettigrew; and Dr Thomas King, Medical Link to European Commission article.. More information about the Horizon 2020 project..
Ungdomsmottagningen örebro åldersgräns

LUND Sweden, Dec. 7, 2020 /PRNewswire/ --Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber, Senior Director of Investor Relations has stepped down from her position to pursue other opportunities

Hos Nordnet kan du handla från 0 kr i courtage.